The unique myeloperoxidase formulation developed by Exoxemis holds the
promise of a breakthrough in the field of surgical site infection prevention.
Surgical site infection (SSI) is an important and persistent problem causing
substantial morbidity, mortality, and cost.
Large potential market
With close to 40 million operations performed annually in the United
States, the potential market for SSI prevention products is projected
to reach several billion dollars. Strong, steady growth of this market
is driven by increasing numbers of elderly, immunocompromised patients,
high risk surgeries, drug resistant strains, outpatient surgeries, and
shorter hospital stays. With antimicrobial resistance posing a growing
threat, there are few, if any, locally administered alternatives for intra-operative
prevention of SSI.
The Exoxemis MPO system addresses the clinical demand for new preventive
and therapeutic approaches that effectively respond to the growing problem
of surgical site infections. Our Surgical Site Infection Prevention formulation
is expected to enter Phase I testing within a year and is currently available